Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 404368, 10 pages
http://dx.doi.org/10.1155/2015/404368
Research Article

All-Trans Retinoic Acid Induces Proliferation, Survival, and Migration in A549 Lung Cancer Cells by Activating the ERK Signaling Pathway through a Transcription-Independent Mechanism

1Departamento de Ciencias Naturales, Universidad Autónoma Metropolitana, Unidad Cuajimalpa, Avenida Vasco de Quiroga 4871, 05348 Colonia Santa Fe Cuajimalpa, DF, Mexico
2Facultad de Enfermería, Universidad Autónoma de San Luis Potosí, Avenida Niño Artillero 130, 78240 Zona Universitaria, SLP, Mexico
3Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del IPN, Avenida Instituto Politécnico Nacional 2508, 14740 Colonia San Pedro Zacatenco, DF, Mexico

Received 8 December 2014; Accepted 2 March 2015

Academic Editor: M. Ruzzene

Copyright © 2015 Reyna Sara Quintero Barceinas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Furrukh, I. A. Burney, S. Kumar, K. F. Zahid, and M. Al-Moundhri, “Improving outcomes in advanced lung cancer: maintenance therapy in non-small-cell lung carcinoma,” Sultan Qaboos University Medical Journal, vol. 13, no. 1, pp. 3–18, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. F. S. Farhat and W. Houhou, “Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?” Therapeutic Advances in Medical Oncology, vol. 5, no. 4, pp. 249–270, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Han, T. Fukazawa, T. Yamatsuji et al., “Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and Retinoic acids,” PLoS ONE, vol. 5, no. 11, Article ID e13834, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. E. J. Choi, Y. M. Whang, S. J. Kim et al., “Combinational treatment with retinoic acid derivatives in non-small cell lung carcinoma in vitro,” Journal of Korean Medical Science, vol. 22, pp. S52–S60, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Luo, M. Lin, L. Li, B. Yang, and Q. He, “The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway,” PLoS ONE, vol. 6, no. 11, Article ID e27298, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Bushue and Y.-J. Y. Wan, “Retinoid pathway and cancer therapeutics,” Advanced Drug Delivery Reviews, vol. 62, no. 13, pp. 1285–1298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Altucci and H. Gronemeyer, “The promise of retinoids to fight against cancer,” Nature Reviews Cancer, vol. 1, no. 3, pp. 181–193, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. M. P. Stavridis, B. J. Collins, and K. G. Storey, “Retinoic acid orchestrates fibroblast growth factor signalling to drive embryonic stem cell differentiation,” Development (Cambridge, England), vol. 137, no. 6, pp. 881–890, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Dave, R. Nanduri, H. K. Dkhar et al., “Nuclear MEK1 sequesters PPARγ and bisects MEK1/ERK signaling: a non-canonical pathway of retinoic acid inhibition of adipocyte differentiation,” PLoS ONE, vol. 9, no. 6, Article ID e100862, 2014. View at Publisher · View at Google Scholar
  11. A. García-Regalado, M. Vargas, A. García-Carrancá, E. Aréchaga-Ocampo, and C. H. González-De la Rosa, “Activation of Akt pathway by transcription-independent mechanisms of retinoic acid promotes survival and invasion in lung cancer cells,” Molecular Cancer, vol. 12, no. 1, article 44, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Aggarwal, S.-W. Kim, K. Cheon, F. H. Tabassam, J.-H. Yoon, and J. S. Koo, “Nonclassical action of retinoic acid on the activation of the cAMP response element-binding protein in normal human bronchial epithelial cells,” Molecular Biology of the Cell, vol. 17, no. 2, pp. 566–575, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Masiá, S. Alvarez, A. R. de Lera, and D. Barettino, “Rapid, nongenomic actions of retinoic acid on phosphatidylinositol-3-kinase signaling pathway mediated by the retinoic acid receptor,” Molecular Endocrinology, vol. 21, no. 10, pp. 2391–2402, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Chen and J. L. Napoli, “All-trans-retinoic acid stimulates translation and induces spine formation in hippocampal neurons through a membrane-associated RARα,” The FASEB Journal, vol. 22, no. 1, pp. 236–245, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Huo, D. Cui, X. Yang, Z. Gao, K. Trier, and J. Zeng, “All-trans retinoic acid modulates mitogen-activated protein kinase pathway activation in human scleral fibroblasts through retinoic acid receptor beta,” Molecular Vision, vol. 19, pp. 1795–1803, 2013. View at Google Scholar · View at Scopus
  16. S. Toma, L. Isnardi, P. Raffo et al., “RARα antagonist RO 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines,” International Journal of Cancer, vol. 78, no. 1, pp. 86–94, 1998. View at Publisher · View at Google Scholar
  17. A. T. Johnson, L. Wang, S. J. Gillett, and R. A. S. Chandraratna, “High affinity retinoic acid receptor antagonists: analogs of AGN 193109,” Bioorganic & Medicinal Chemistry Letters, vol. 9, no. 4, pp. 573–576, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. A. B. Turke, Y. Song, C. Costa et al., “MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors,” Cancer Research, vol. 72, no. 13, pp. 3228–3237, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. Z. Lu and S. Xu, “ERK1/2 MAP kinases in cell survival and apoptosis,” IUBMB Life, vol. 58, no. 11, pp. 621–631, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. S. V. Kyosseva, “Mitogen-activated protein kinase signaling,” in International Review of Neurobiology, S. John, Ed., vol. 59, pp. 201–220, Academic Press, 2004. View at Google Scholar
  21. A. Zanotto-Filho, M. Cammarota, D. P. Gelain et al., “Retinoic acid induces apoptosis by a non-classical mechanism of ERK1/2 activation,” Toxicology in Vitro, vol. 22, no. 5, pp. 1205–1212, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Keidel, P. LeMotte, and C. Apfel, “Different agonist- and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping,” Molecular and Cellular Biology, vol. 14, no. 1, pp. 287–298, 1994. View at Google Scholar · View at Scopus
  23. A. Piskunov and C. Rochette-Egly, “A retinoic acid receptor RARα pool present in membrane lipid rafts forms complexes with G protein αQ to activate p38MAPK,” Oncogene, vol. 31, no. 28, pp. 3333–3345, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Dey, P. K. de, M. Wang et al., “CSK controls Retinoic Acid Receptor (RAR) signaling: a RAR-c-SRC signaling axis is required for neuritogenic differentiation,” Molecular and Cellular Biology, vol. 27, no. 11, pp. 4179–4197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Piu, N. K. Gauthier, and F. Wang, “β-arrestin 2 modulates the activity of nuclear receptor RAR β2 through activation of ERK2 kinase,” Oncogene, vol. 25, no. 2, pp. 218–229, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Hoyos, A. Imam, I. Korichneva, E. Levi, R. Chua, and U. Hammerling, “Activation of c-Raf kinase by ultraviolet light: regulation by retinoids,” The Journal of Biological Chemistry, vol. 277, no. 26, pp. 23949–23957, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. B. C. Duckworth and L. C. Cantley, “Conditional inhibition of the mitogen-activated protein kinase cascade by wortmannin: dependence on signal strength,” The Journal of Biological Chemistry, vol. 272, no. 44, pp. 27665–27670, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. H.-F. Yuen, O. Abramczykd, G. Montgomery et al., “Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells,” Bioscience Reports, vol. 32, no. 4, pp. 413–422, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Carracedo, L. Ma, J. Teruya-Feldstein et al., “Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer,” The Journal of Clinical Investigation, vol. 118, no. 9, pp. 3065–3074, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Ebi, C. Costa, A. C. Faber et al., “PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 52, pp. 21124–21129, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. V. Serra, M. Scaltriti, L. Prudkin et al., “PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer,” Oncogene, vol. 30, no. 22, pp. 2547–2557, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Geradts, J. Y. Chen, E. K. Russell, J. R. Yankaskas, L. Nieves, and J. D. Minna, “Human lung cancer cell lines exhibit resistance to retinoic acid treatment,” Cell Growth & Differentiation, vol. 4, no. 10, pp. 799–809, 1993. View at Google Scholar · View at Scopus
  33. W. J. Petty, N. Li, A. Biddle et al., “A novel retinoic acid receptor β isoform and retinoid resistance in lung carcinogenesis,” Journal of the National Cancer Institute, vol. 97, no. 22, pp. 1645–1651, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Kawabata, S. Tanimura, K. Asai, R. Kawasaki, Y. Matsumaru, and M. Kohno, “Up-regulation of pro-apoptotic protein bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor,” The Journal of Biological Chemistry, vol. 287, no. 13, pp. 10289–10300, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Miyoshi, H. Hamada, N. Hamaguchi et al., “Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo,” International Journal of Oncology, vol. 41, no. 2, pp. 449–456, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Zaragozá, A. Gimeno, V. J. Miralles et al., “Retinoids induce MMP-9 expression through RARα during mammary gland remodeling,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 292, no. 4, pp. E1140–E1148, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Pan, Y.-L. Kao, S. Joshi, S. Jeetendran, D. DiPette, and U. S. Singh, “Activation of Rac1 by phosphatidylinositol 3-kinase in vivo: role in activation of mitogen-activated protein kinase (MAPK) pathways and retinoic acid-induced neuronal differentiation of SH-SY5Y cells,” Journal of Neurochemistry, vol. 93, no. 3, pp. 571–583, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. N. A. Mack, H. J. Whalley, S. Castillo-Lluva, and A. Malliri, “The diverse roles of Rac signaling in tumorigenesis,” Cell Cycle, vol. 10, no. 10, pp. 1571–1581, 2011. View at Publisher · View at Google Scholar · View at Scopus